NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Angiex

Angiex

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://angiex.com/

Last Round

VC Round

Nov 17, 2025

Total Funding Raised

$48.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Angiex is a biopharmaceutical company that develops vascular-targeted biotherapeutics and nuclear-delivered antibody-drug conjugates for the treatment of solid cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugateADConcologycancer therapeuticssolid tumor treatmenttumor vasculatureclinical trialsdrug discoverytargeted therapybiotechout-licensinginvestigational new drugINDprecision medicinepharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Angiex Comps

Public and private peers based on sector, stage, and business model.

Angiex comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Angiex Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundNov 17, 2025
Series BAug 18, 2021
SeedJul 27, 2017
GrantNov 2, 2016

Key People

Founding team and executive leadership

Jeff Sacher

Chief Financial Officer

Executive Team

Glen Weiss

Chief Medical Officer, Scientific Advisory Board Member

Executive Team

Angiex Investors

Notable investors and investment history

Angiex investors
InvestorRounds
Paulson Investment CompanyVC Round
Presight CapitalSeries B
Starling VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Presented in vivo data for AGX101, a cancer therapy candidate.

  • Apr 17, 2026

    Presenting preclinical data for AGX101 at the AACR Annual Meeting.

Angiex Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Angiex Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Angiex's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range10
Year Founded2015
Last FundingNov 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.